Why the study?
Does low-level anticoagulation combined with low-dose dipyridamole reduce thromboembolic and hemorrhagic events compared to standard anticoagulation monotherapy in young rheumatic patients with a St Jude mitral valve prosthesis?
Population
486 young rheumatic patients with a St Jude mitral valve prosthesis
Comparison
Low-level anticoagulation primarily with… vs Standard anticoagulation monotherapy primarily…
Design
Cohort
Follow-up
1712.6 patient-years (total)
Authors
Loading...
May support lower-intensity regimens in young rheumatic mitral prosthesis patients; hypothesis-generating pending randomized confirmation.
Does low-level anticoagulation combined with low-dose dipyridamole reduce thromboembolic and hemorrhagic events compared to standard anticoagulation monotherapy in young rheumatic patients with a St Jude mitral valve prosthesis?
In young rheumatic patients with mechanical mitral valves, a lower INR target combined with low-dose dipyridamole significantly reduced thromboembolic and hemorrhagic complications compared to standard higher-target INR monotherapy.
Ahmed Hassouna (2000) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: